Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonists.
Corinna Lang-SchwarzBalint MelcherTheresa DregeliesZahra NorouzzadehStefanie Rund-KüffnerKlaus Lang-SchwarzMichael ViethWilliam SterlacciPublished in: International journal of colorectal disease (2021)
The budding/TIL combination identified subgroups in stage II and III colon cancer with and without benefit from adjuvant treatment. The results this study suggest that the combination of budding and TILs as tumor-host antagonists might be an additional helpful tool in adjuvant treatment decisions in stage II and III colon cancer.
Keyphrases